Weill Cornell Medicine Enterprise Innovation empowers exceptional patient care through identifying and nurturing commercially viable and life-changing medical innovations. By bridging academic research and industrial commercialization, WCM Enterprise Innovation accelerates the application of vital innovations to ultimately improve patient care and outcomes.
How CTL Supports Weill Cornell Medicine Enterprise Innovation
Aside from serving the technology transfer needs of Cornell University, CTL is also an integral part of Weill Cornell Medicine Enterprise Innovation. Weill Cornell Medicine Enterprise Innovation consists of the Center for Technology Licensing (CTL) at Weill Cornell, the Office of BioPharma Alliances and Research Collaborations, BioVenture eLab, and the Daedalus Fund.
Combining the full power of business development expertise with the rich history of Weill Cornell Medicine and the breadth of Cornell University, Weill Cornell Medicine Enterprise Innovation provides a bridge between academic researchers and industry stakeholders, brokering engagements and alliances, engaging with and educating faculty about biotech commercialization and business development—which includes patenting, licensing, and marketing —and developing entrepreneurial programming, education, mentoring, and other resources.
Our dedicated team of experts guides faculty and trainees on accelerating innovation to commercialization, connects investors and businesses with talents, and ultimately improves patient care and outcomes. To learn more about Weill Cornell Medicine Enterprise Innovation and contact our business development professionals, please email email@example.com.